Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUGMENT: Lenalidomide + Rituximab in R/R Indolent Lymphoma
NCT01938001Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2013
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of lenalidomide in follicular lymphoma (FL), marginal zone lymphoma (MZL), sponsored by Celgene Corporation. Started Nov 2013; status: completed.
02
Drugs
lenalidomide
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT01938001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01938001.